CAI•prnewswire•
Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
Summary
Full year revenue growth of approximately 94% driven by strong performance in molecular profiling services IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 12, 2026 by prnewswire